TuesdayAug 24, 2021 12:41 pm

Nearly 30% of Suicide-Prone People Have Regained Full Psychological Well-Being

A nationally representative study that was recently conducted reports that about 29% of participants who had a suicide attempt history had achieved a state of complete mental health. In order to make that determination, participants had to report high levels of psychological and social well-being in the last month, almost daily life satisfaction or happiness in the last month, and freedom from suicidality and mental ailments such as substance dependence and psychiatric disorders to be considered in complete mental health. The study was published in the “Archives of Suicide Research.” Prof. Esme Fuller-Thomson from the University of Toronto, the study’s…

Continue Reading

MondayAug 23, 2021 12:05 pm

ASTRO Releases Clinical Guidelines for Soft-Tissue Sarcoma Radiation in Adults

The American Society for Radiation Oncology recently released a new clinical guideline that offers guidance on the utilization of radiation therapy in the treatment of soft-tissue sarcoma patients. The new guideline was published in “Practical Radiation Oncology.” The recommendations include treatment planning, radiation techniques and optimal radiation dosing for patients with operable, localized soft-tissue sarcoma of the extremities, including legs and arms and the abdominal wall and chest wall. Soft-tissue sarcoma is rare, making up only 1% of malignancies in adults. The condition is known to be lethal and comprises more than 50 subtypes, which are all different. The tumors…

Continue Reading

MondayAug 23, 2021 10:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

Continue Reading

FridayAug 20, 2021 11:08 am

Current Bladder Cancer Treatments May Adversely Affect Patients’ Psychosocial Well-Being

A study that was recently published in the “International Journal of Urological Nursing” found that intravesical therapy affected the physical, emotional and social well-being of patients who suffered from non-muscle invasive bladder cancer. The participants of the study underwent intravesical therapy together with either mitomycine (“MMC”) or Bacillus Calmette-Guerin (“BCG”) treatments. The objective of the authors of the study was to evaluate the psychosocial issues these study subjects experienced during therapy and what effects those challenges triggered. In their report, the authors stated that the patients struggled to cope with treatment side effects, adding that this was in addition to…

Continue Reading

FridayAug 20, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine  In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing  This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research  Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health  Mind Cure…

Continue Reading

ThursdayAug 19, 2021 11:23 am

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

Continue Reading

ThursdayAug 19, 2021 11:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond The San Diego-based pharmaceutical company, Tryp…

Continue Reading

ThursdayAug 19, 2021 10:07 am

Brain Scientific Inc. (BRSF) Addresses Growing Epilepsy Problem With Portable Low-Cost Brain Monitoring Devices

CDC reports epilepsy is growing problem, 3.4 million people afflicted in the US According to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same period Brain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year More Americans are suffering from epilepsy than ever before, according to a report by the Center for Disease Control (“CDC”) that states that at least 3.4 million people live with the disorder in the United States (https://ibn.fm/PmF2b). Brain Scientific (OTCQB:…

Continue Reading

ThursdayAug 19, 2021 9:30 am

Chronic Pain May Influence How Your Brain Processes Emotions

A study conducted by researchers from NeuRA and the University of New South Wales Sydney has found that individuals with chronic pain have a neurotransmitter imbalance in the area of the brain that is responsible for regulating emotions. The study was published in the “European Journal of Pain.” Estimates show that more than three million individuals in Australia are plagued with chronic pain, which can affect many parts of an individual’s life; more than half of these individuals also experienced depression and anxiety disorders. The researchers hypothesize that the neurotransmitter imbalance could be making it more difficult for these individuals…

Continue Reading

WednesdayAug 18, 2021 12:15 pm

Routine Cancer Screening Declines During Pandemic

At the onset of the pandemic, restrictions on moving around were implemented, with social distancing and other measures being taken to avoid virus spread. As people have adjusted to a “new”  normal, fewer and fewer individuals have been returning to their physicians for their annual cancer screenings. Cancer screening is basically getting checked for cancer by your physician before you begin displaying any symptoms. Regular screening may find colorectal, cervical and breast cancers in their early stages when treatment will be more effective, in comparison to late-stage diagnoses. Estimates from the Centers for Disease Control and Prevention show that the…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050